Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140

被引:131
作者
Earl, PL
Sugiura, W
Montefiori, DC
Broder, CC
Lee, SA
Wild, C
Lifson, J
Moss, B
机构
[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
[2] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[3] Panacos Pharmaceut, Gaithersburg, MD 20877 USA
[4] NCI, Frederick Canc Res & Dev Ctr, Retroviral Pathogenesis Lab, AIDS Vaccine Program,SAIC, Frederick, MD 21702 USA
关键词
D O I
10.1128/JVI.75.2.645-653.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R W Doms, and B. Moss, J, Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHN-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 79 条
  • [1] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [2] Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells
    Baldridge, JR
    McGraw, TS
    Paoletti, A
    Buchmeier, MJ
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (01) : 755 - 758
  • [3] Vaccination with HIV 1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
    Barnett, SW
    Rajasekar, S
    Legg, H
    Doe, B
    Fuller, DH
    Haynes, JR
    Walker, CM
    Steimer, KS
    [J]. VACCINE, 1997, 15 (08) : 869 - 873
  • [4] Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
    Beddows, S
    Lister, S
    Cheingsong, R
    Bruck, C
    Weber, J
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (02) : 1740 - 1745
  • [5] NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZED WITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1
    BELSHE, RB
    GRAHAM, BS
    KEEFER, MC
    GORSE, GJ
    WRIGHT, P
    DOLIN, R
    MATTHEWS, T
    WEINHOLD, K
    BOLOGNESI, DP
    SPOSTO, R
    STABLEIN, DM
    TWADDELL, T
    BERMAN, PW
    GREGORY, T
    IZU, AE
    WALKER, MC
    FAST, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06): : 475 - 480
  • [6] Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
    Belshe, RB
    Gorse, GJ
    Mulligan, MJ
    Evans, TG
    Keefer, MC
    Excler, JL
    Duliege, AM
    Tartaglia, J
    Cox, WI
    McNamara, J
    Hwang, KL
    Bradney, A
    Montefiori, D
    Weinhold, KJ
    [J]. AIDS, 1998, 12 (18) : 2407 - 2415
  • [7] PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160
    BERMAN, PW
    GREGORY, TJ
    RIDDLE, L
    NAKAMURA, GR
    CHAMPE, MA
    PORTER, JP
    WURM, FM
    HERSHBERG, RD
    COBB, EK
    EICHBERG, JW
    [J]. NATURE, 1990, 345 (6276) : 622 - 625
  • [8] A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
    Binley, JM
    Sanders, RW
    Clas, B
    Schuelke, N
    Master, A
    Guo, Y
    Kajumo, F
    Anselma, DJ
    Maddon, PJ
    Olson, WC
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (02) : 627 - 643
  • [9] FUSOGENIC SELECTIVITY OF THE ENVELOPE GLYCOPROTEIN IS A MAJOR DETERMINANT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TROPISM FOR CD4(+) T-CELL LINES VS PRIMARY MACROPHAGES
    BRODER, CC
    BERGER, EA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (19) : 9004 - 9008
  • [10] ANTIGENIC IMPLICATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE QUATERNARY STRUCTURE - OLIGOMER-SPECIFIC AND OLIGOMER-SENSITIVE MONOCLONAL-ANTIBODIES
    BRODER, CC
    EARL, PL
    LONG, D
    ABEDON, ST
    MOSS, B
    DOMS, RW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (24) : 11699 - 11703